{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.382","value":"2.53"},{"groupId":"OG001","spread":"1.901","value":"3.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.176","value":"2.96"},{"groupId":"OG001","spread":"1.276","value":"3.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Cycle 3 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with pcALCL received brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG000","title":"pcALCL: Brentuximab Vedotin"},{"description":"Participants with MF received brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).","id":"OG001","title":"MF: Brentuximab Vedotin 1.8 mg/kg"}],"paramType":"MEAN","populationDescription":"The PK population included participants with sufficient dose and PK data to reliably estimate PK parameters as determined by a clinical pharmacologist. Here 'Number analyzed' is the number of participants with evaluable data at the specified time-point.","reportingStatus":"POSTED","timeFrame":"Day 1 pre-dose and 30 minutes after infusion ended in Cycles 1 and 3","title":"Cmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin","type":"SECONDARY","unitOfMeasure":"ng/mL"}